摘要
目的探讨放化疗联合靶向药物治疗晚期胆道恶性肿瘤的效果和安全性。方法选择2014年1月至2016年1月我院肿瘤科收治的70例晚期胆道恶性肿瘤患者作为研究对象,按照随机数字表法将其分为对照组(n=30)和观察组(n=40)。对照组实施常规放疗、化疗,观察组在其基础上加用贝伐珠单抗。比较两组临床疗效、生存期、肿瘤标志物水平、不良反应发生情况及生存质量评分。结果观察组的ORR、DCR均高于对照组,PFS、OS均长于对照组,差异具有统计学意义(P<0.05)。治疗后,两组CEA、CA125、CA153水平明显低于治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。观察组恶心呕吐、白细胞下降、血小板下降、皮疹发生率与对照组相比较,差异无统计学意义(P>0.05)。治疗后3个月,观察组的各项生存质量评分均高于对照组,差异具有统计学意义(P<0.05)。结论采用放化疗联合靶向药物治疗晚期胆道恶性肿瘤患者,可发挥良好的近期疗效,延长患者生存期,改善远期预后,且安全性良好。
Objective To investigate the efficacy and safety of radiotherapy and chemotherapy combined with targeted drugs in the treatment of advanced biliary malignant tumor.Methods Seventy patients with advanced biliary malignant tumor admitted in the oncology department of our hospital from January 2014 to January 2016 were selected as the study objects.The patients were divided into control group(n=30)and observation group(n=40)according to the random number table method.The control group was treated with conventional radiotherapy and chemotherapy,and the observation group was treated with bevacizumab on this basis.The clinical efficacy,survival time,tumor markers levels,adverse reactions and quality of life scores were compared between the two groups.Results The ORR and DCR of the observation group were higher than those of the control group,and the PFS and OS of the observation group were longer than those of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CEA,CA125 and CA153 in the two groups were significantly lower than those before treatment,and those of the observation group were lower than the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidences of nausea and vomiting,leucopenia,thrombocytopenia and rash between the two groups(P>0.05).Three months after treatment,the quality of life scores of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).Conclusion Radiotherapy and chemotherapy combined with targeted drugs applied to patients with advanced biliary malignant tumor can play a good short-term effect,prolong the survival period of patients,and improve the long-term prognosis,with good safety.
作者
张进儒
郑安婕
刘海明
祁涛
ZHANG Jin-ru;ZHENG An-jie;LIU Hai-ming;QI Tao(Oncology Department,Baoji Hi-tech People's Hospital,Baoji 721013,China)
出处
《临床医学研究与实践》
2020年第9期26-27,62,共3页
Clinical Research and Practice
关键词
晚期胆道恶性肿瘤
放疗
化疗
靶向药物
贝伐珠单抗
advanced biliary malignant tumor
radiotherapy
chemotherapy
targeted drugs
bevacizumab
